Multivariate analysis of variables associated with an increased OS and survival from relapse
| . | Hazard ratio . | Confidence interval . | P . |
|---|---|---|---|
| OS | |||
| Max resp ≥VGPR | 1.353 | 1.048-1.746 | .020 |
| IgG | 1.353 | 1.059-1.726 | .016 |
| Intensive pathway | 1.677 | 1.297-2.167 | <.000 |
| Relapse type | .005 | ||
| PO vs PLC | 1.480 | 1.169-1.872 | .001 |
| PO vs FLC escape | 1.130 | 0.772-1.655 | .528 |
| Survival from relapse | |||
| Intensive pathway | 1.375 | 1.066-1.775 | .014 |
| Relapse type | .001 | ||
| PO vs PLC | 1.560 | 1.232-1.975 | .000 |
| PO vs FLC escape | 1.284 | 0.873-1.887 | .204 |
| . | Hazard ratio . | Confidence interval . | P . |
|---|---|---|---|
| OS | |||
| Max resp ≥VGPR | 1.353 | 1.048-1.746 | .020 |
| IgG | 1.353 | 1.059-1.726 | .016 |
| Intensive pathway | 1.677 | 1.297-2.167 | <.000 |
| Relapse type | .005 | ||
| PO vs PLC | 1.480 | 1.169-1.872 | .001 |
| PO vs FLC escape | 1.130 | 0.772-1.655 | .528 |
| Survival from relapse | |||
| Intensive pathway | 1.375 | 1.066-1.775 | .014 |
| Relapse type | .001 | ||
| PO vs PLC | 1.560 | 1.232-1.975 | .000 |
| PO vs FLC escape | 1.284 | 0.873-1.887 | .204 |
FLC escape, serum FLC escape relapse; IgG, IgG isotype myeloma; Intensive pathway, treatment in the intensive pathway of MRC Myeloma IX trial; Max resp, maximum response; VGPR, very good partial response.